newsfilter
← Latest News
Business Wire·

Edwards SAPIEN 3 TAVR Delivers Proven Long-term Benefits and Valve Performance, New Data Presented at TCT 2025

EW

SAPIEN 3, which showed superiority at 1 year, also demonstrates compelling outcomes equivalent to surgery at seven years Edwards Lifesciences (NYSE:EW) today announced seven-year data from the PARTNER 3 trial,